|Bid||0.00 x 800|
|Ask||0.00 x 1100|
|Day's Range||59.21 - 61.47|
|52 Week Range||37.44 - 90.98|
|Beta (3Y Monthly)||3.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
Ultragenyx Pharmaceutical Inc NASDAQ/NGS:RAREView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding RARE are favorable, with net inflows of $2.65 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Emil Kakkis launched Ultragenyx Pharmaceutical in Novato and the EveryLife Foundation for Rare Diseases, lobbying for legislative changes to make it easier to develop rare disease drugs.
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In 2010 Emil Kakkis was appointed CEO of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). This analysis aims first to...
The Novato, California-based company said it had a loss of $1.82 per share. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Legendary investors such as Jeffrey Talpins and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don't publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That's why we analyze the […]
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This week's Health Care Digest explores growing companies and introduces our new health care reporter, Hannah Norman.
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.